Anderson Heart Partners with Azura Vascular Care & National Cardiovascular Partners

Anderson Heart, PC (Anderson Heart or AH), an independent cardiology and vascular surgery practice headquartered in Anderson, South Carolina, has partnered with Azura Vascular Care and National Cardiovascular Partners, LP, together wholly owned by Fresenius Medical Care North America, to form a newly created joint venture that completes an equity recapitalization and focuses on a growth strategy of physician recruitment and providing high-quality medical care to patients throughout South Carolina, at the advice of The Capital Corporation

The Capital Corporation, a boutique investment bank headquartered in Greenville, South Carolina, offering particular expertise in the health services sector, served as the exclusive investment banking advisor to Anderson Heart on the transaction.

Anderson Heart was formed in 2006 as an independent cardiology medical practice by founder and current Chief Executive Officer, Dr. Brent McLaurin. Since formation, AH added three additional physicians including one cardiologist and two vascular surgeons. In 2017, AH designed and constructed a wholly-owned, freestanding, independent clinic from which its four physicians conduct their practice of medicine.

Anderson Heart provides the highest-quality medical services to its patients from its owned clinic and local hospitals as necessary. Further, AH does so at lower overall cost to patients and third-party reimbursors such as the Centers for Medicare and Medicaid Services (“CMS”) and numerous independent health insurance companies. CMS is part of the Department of Health and Human Services and oversees the U.S. government’s Medicare and Medicaid programs.

Azura Vascular Care, a division of Fresenius Medical Care North America, is a national leader in the field of vascular specialty services. Operating and managing outpatient vascular care and ambulatory surgery centers throughout the United States and Puerto Rico, Azura’s physicians and trained medical specialists perform minimally invasive procedures focusing on excellence in clinical outcomes and delivering a great customer experience to patients with various vascular conditions that can be treated safely in an outpatient setting.

National Cardiovascular Partners, a division of Fresenius Medical Care North America, partners with physicians to create, sustain and grow independent ambulatory surgery centers and catheterization labs. Its focus is on hybrid surgery center and outpatient cardiac catheterization lab services, in partnership with physician entrepreneurs. NCP currently operates surgery centers and physician practices throughout the U.S. For more information, please visit the NCP website at www.ncplp.com.

The Capital Corporation: Now in its 30th year of operation, The Capital Corporation continues to provide its publicly traded and privately held middle-market client companies quality advisory services to help them achieve their financial objectives. With hundreds of closed transactions, The Capital Corporation is one of the most successful middle-market investment banking firms in the country, differentiated by its team’s experience, commitment, and unwavering focus on achieving client objectives. As a member of IMAP, The Capital Corporation is part of the world’s largest alliance of independent M&A advisory firms offering local expertise and global connections through more than 60 offices in over 40 countries.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

The Evolut ™ FX+ TAVR system leverages market-leading valve performance with addition of larger windows to facilitate coronary access
The study was an analysis of AstraZeneca’s Phase 2 52-Week clinical trial of tralokinumab in patients with Idiopathic Pulmonary Fibrosis (IPF). The patient data from the trial was processed with Brainomix’s e-Lung tool. The tool is uniquely powered by the weighted reticulovascular score (WRVS), a novel biomarker that incorporates reticular opacities and vascular structures of the lung.
“Since the algorithm for matching patients with donors is changing across for all organs, this was a prime time to better understand whether transplant team decisions to accept a donated organ varied by patient race and gender,” she said. “We wanted to understand how the process of receiving a transplant after listing varied by race and gender, and the combination of the two, so that steps can be taken to make that process more equitable," said Khadijah Breathett, MD.
The Mount Sinai study found that primary care physicians’ approach reflects a dearth of evidence-based guidance for lung cancer screening shared decision-making in patients with complex comorbidities
This is the first ever transplantation of a genetically engineered porcine kidney into a living human recipient.

By using this website you agree to accept Medical Device News Magazine Privacy Policy

Exit mobile version